SCHEMBL20674623

SCHEMBL20674623

NS(=O)(=O)c1nc(O)c2ccccn12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LDHA P00338 1/20 0.36
▸ HTR6 P50406 3/20 0.36
▸ BAZ2B Q9UIF8 1/20 0.36
▸ BAZ2A Q9UIF9 1/20 0.36
▸ MAP2K3 P46734 2/20 0.35
▸ PTGS1 P23219 1/20 0.34
▸ PTGS2 P35354 1/20 0.34
▸ FTO Q9C0B1 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.34
▸ DAPK3 O43293 1/20 0.34
▸ JAK2 O60674 1/20 0.34
▸ PRKD3 O94806 1/20 0.34
▸ MAP4K4 O95819 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ CSF1R P07333 1/20 0.34
▸ RET P07949 1/20 0.34
▸ MET P08581 1/20 0.34
▸ PDGFRA P16234 1/20 0.34
▸ PRKACA P17612 1/20 0.34
▸ LTK P29376 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20674631 0.83 BAZ2B (0.41) BAZ2BBAZ2AALDH1A1DAPK3JAK2
SCHEMBL20674637 0.81 BAZ2B (0.37) HTR6BAZ2BBAZ2AALDH1A1DAPK3
SCHEMBL20673881 0.73 BAZ2B (0.36) LDHAHTR6BAZ2BBAZ2AMAP2K3
SCHEMBL20674626 0.71 MAP2K3 (0.60) BAZ2BBAZ2AMAP2K3PTGS1PTGS2
SCHEMBL20674534 0.71 PTPN2 (0.44) BAZ2BBAZ2AALDH1A1GAAHPGD
SCHEMBL20674638 0.70 KEAP1 (0.37) BAZ2BBAZ2AALDH1A1GAAHPGD
SCHEMBL20674509 0.69 ALDH1A1 (0.42) BAZ2BBAZ2AALDH1A1GAAHPGD
SCHEMBL20674621 0.68 BAZ2B (0.46) BAZ2BBAZ2AMAP2K3ALDH1A1GAA
SCHEMBL20674634 0.67 KDM4E (0.41) BAZ2BBAZ2AALDH1A1GAAHPGD
SCHEMBL9796138 0.67 KDM4E (0.47) PTGS1PTGS2ALDH1A1DAPK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200131176-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS PHARMATECH LIMITED (KY) 2020-04-30 — — US disclosed
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase CS PHARMATECH LIMITED (KY) 2019-10-08 — — US disclosed
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE HIGH GREAT INVESTMENT LIMITED (HK) 2019-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase EGFR, ERBB3, ERBB2 LDHA 4026/4885HTR6 3906/4885BAZ2B 583/4885
US-20200131176-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 LDHA 3965/4885HTR6 3946/4885BAZ2B 681/4885
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 LDHA 4026/4885HTR6 3906/4885BAZ2B 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback